Protein disulfide isomerase A3-specific Th1 effector cells infiltrate colon cancer tissue of patients with circulating anti-protein disulfide isomerase A3 autoantibodies

Cristiana Caorsi, Elena Niccolai, Michela Capello, Rosario Vallone, Michelle S. Chattaragada, Brunilda Alushi, Anna Castiglione, Gianni Ciccone, Alessandro Mautino, Paola Cassoni, Lucia De Monte, Sheila M. Álvarez-Fernández, Amedeo Amedei, Massimo Alessio, Francesco Novelli

Research output: Contribution to journalArticle

Abstract

To investigate novel colorectal cancer (CRC)-associated antigens that could be targets of humoral or cellular responses, we analyzed the reactivity of serum from a long-surviving CRC patient (for more than 100 months of follow-up) in clinical remission, by serologic proteome analysis. Two-dimensional Western blotting (2D-WB) and mass spectrometry analysis revealed a strong reactivity of this serum against protein disulfide isomerase A3 (PDIA3). Anti-PDIA3 antibodies are not a diagnostic marker of CRC, 2D-WB and Luminex analysis revealed that they were equally present in about 10% of sera from healthy subjects and CRC patients. Kaplan-Meier analysis of survival in CRC patient cohort, after 48 months of follow-up, showed a trend of higher survival in patients with increased levels of autoantibodies to PDIA3. Therefore, the interplay between the presence of these antibodies and T-cell response was investigated. Peripheral blood T cells from CRC patients with high immunoglobulin G (IgG) reactivity to PDIA3 also secreted interferon gamma (IFN-γ) when stimulated in vitro with recombinant PDIA3, whereas those from CRC with low IgG reactivity to PDIA3 did not. PDIA3-pulsed dendritic cells efficiently induced proliferation and IFN-γ production of autologous CD4+ and CD8+ T cells. Finally, ex vivo analysis of tumor-infiltrating T lymphocytes from CRC patients with autoantibodies to PDIA3 revealed that PDIA3-specific Th1 effector cells accumulated in tumor tissue. These data indicate that the presence of autoantibodies to PDIA3 favors the development of an efficient and specific T-cell response against PDIA3 in CRC patients. These results may be relevant for the design of novel immunotherapeutic strategies in CRC patients.
Original languageEnglish
Pages (from-to)17 - 28
Number of pages12
JournalTranslational Research
Volume171
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Protein Disulfide-Isomerases
Th1 Cells
Autoantibodies
Colonic Neoplasms
Colorectal Neoplasms
Tissue
T-cells
T-Lymphocytes
Interferon-gamma
Tumors
Immunoglobulin G
Tumor-Infiltrating Lymphocytes
Survival
Antibodies
Kaplan-Meier Estimate
Proteome
Serum
Recombinant Proteins
Dendritic Cells
Mass spectrometry

ASJC Scopus subject areas

  • Medicine(all)
  • Public Health, Environmental and Occupational Health
  • Biochemistry, medical

Cite this

Protein disulfide isomerase A3-specific Th1 effector cells infiltrate colon cancer tissue of patients with circulating anti-protein disulfide isomerase A3 autoantibodies. / Caorsi, Cristiana; Niccolai, Elena; Capello, Michela; Vallone, Rosario; Chattaragada, Michelle S.; Alushi, Brunilda; Castiglione, Anna; Ciccone, Gianni; Mautino, Alessandro; Cassoni, Paola; De Monte, Lucia; Álvarez-Fernández, Sheila M.; Amedei, Amedeo; Alessio, Massimo; Novelli, Francesco.

In: Translational Research, Vol. 171, 01.05.2016, p. 17 - 28.

Research output: Contribution to journalArticle

Caorsi, C, Niccolai, E, Capello, M, Vallone, R, Chattaragada, MS, Alushi, B, Castiglione, A, Ciccone, G, Mautino, A, Cassoni, P, De Monte, L, Álvarez-Fernández, SM, Amedei, A, Alessio, M & Novelli, F 2016, 'Protein disulfide isomerase A3-specific Th1 effector cells infiltrate colon cancer tissue of patients with circulating anti-protein disulfide isomerase A3 autoantibodies', Translational Research, vol. 171, pp. 17 - 28. https://doi.org/10.1016/j.trsl.2015.12.013
Caorsi, Cristiana ; Niccolai, Elena ; Capello, Michela ; Vallone, Rosario ; Chattaragada, Michelle S. ; Alushi, Brunilda ; Castiglione, Anna ; Ciccone, Gianni ; Mautino, Alessandro ; Cassoni, Paola ; De Monte, Lucia ; Álvarez-Fernández, Sheila M. ; Amedei, Amedeo ; Alessio, Massimo ; Novelli, Francesco. / Protein disulfide isomerase A3-specific Th1 effector cells infiltrate colon cancer tissue of patients with circulating anti-protein disulfide isomerase A3 autoantibodies. In: Translational Research. 2016 ; Vol. 171. pp. 17 - 28.
@article{3485eba1ba1545f99938050a9515f5f7,
title = "Protein disulfide isomerase A3-specific Th1 effector cells infiltrate colon cancer tissue of patients with circulating anti-protein disulfide isomerase A3 autoantibodies",
abstract = "To investigate novel colorectal cancer (CRC)-associated antigens that could be targets of humoral or cellular responses, we analyzed the reactivity of serum from a long-surviving CRC patient (for more than 100 months of follow-up) in clinical remission, by serologic proteome analysis. Two-dimensional Western blotting (2D-WB) and mass spectrometry analysis revealed a strong reactivity of this serum against protein disulfide isomerase A3 (PDIA3). Anti-PDIA3 antibodies are not a diagnostic marker of CRC, 2D-WB and Luminex analysis revealed that they were equally present in about 10{\%} of sera from healthy subjects and CRC patients. Kaplan-Meier analysis of survival in CRC patient cohort, after 48 months of follow-up, showed a trend of higher survival in patients with increased levels of autoantibodies to PDIA3. Therefore, the interplay between the presence of these antibodies and T-cell response was investigated. Peripheral blood T cells from CRC patients with high immunoglobulin G (IgG) reactivity to PDIA3 also secreted interferon gamma (IFN-γ) when stimulated in vitro with recombinant PDIA3, whereas those from CRC with low IgG reactivity to PDIA3 did not. PDIA3-pulsed dendritic cells efficiently induced proliferation and IFN-γ production of autologous CD4+ and CD8+ T cells. Finally, ex vivo analysis of tumor-infiltrating T lymphocytes from CRC patients with autoantibodies to PDIA3 revealed that PDIA3-specific Th1 effector cells accumulated in tumor tissue. These data indicate that the presence of autoantibodies to PDIA3 favors the development of an efficient and specific T-cell response against PDIA3 in CRC patients. These results may be relevant for the design of novel immunotherapeutic strategies in CRC patients.",
author = "Cristiana Caorsi and Elena Niccolai and Michela Capello and Rosario Vallone and Chattaragada, {Michelle S.} and Brunilda Alushi and Anna Castiglione and Gianni Ciccone and Alessandro Mautino and Paola Cassoni and {De Monte}, Lucia and {\'A}lvarez-Fern{\'a}ndez, {Sheila M.} and Amedeo Amedei and Massimo Alessio and Francesco Novelli",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.trsl.2015.12.013",
language = "English",
volume = "171",
pages = "17 -- 28",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Protein disulfide isomerase A3-specific Th1 effector cells infiltrate colon cancer tissue of patients with circulating anti-protein disulfide isomerase A3 autoantibodies

AU - Caorsi, Cristiana

AU - Niccolai, Elena

AU - Capello, Michela

AU - Vallone, Rosario

AU - Chattaragada, Michelle S.

AU - Alushi, Brunilda

AU - Castiglione, Anna

AU - Ciccone, Gianni

AU - Mautino, Alessandro

AU - Cassoni, Paola

AU - De Monte, Lucia

AU - Álvarez-Fernández, Sheila M.

AU - Amedei, Amedeo

AU - Alessio, Massimo

AU - Novelli, Francesco

PY - 2016/5/1

Y1 - 2016/5/1

N2 - To investigate novel colorectal cancer (CRC)-associated antigens that could be targets of humoral or cellular responses, we analyzed the reactivity of serum from a long-surviving CRC patient (for more than 100 months of follow-up) in clinical remission, by serologic proteome analysis. Two-dimensional Western blotting (2D-WB) and mass spectrometry analysis revealed a strong reactivity of this serum against protein disulfide isomerase A3 (PDIA3). Anti-PDIA3 antibodies are not a diagnostic marker of CRC, 2D-WB and Luminex analysis revealed that they were equally present in about 10% of sera from healthy subjects and CRC patients. Kaplan-Meier analysis of survival in CRC patient cohort, after 48 months of follow-up, showed a trend of higher survival in patients with increased levels of autoantibodies to PDIA3. Therefore, the interplay between the presence of these antibodies and T-cell response was investigated. Peripheral blood T cells from CRC patients with high immunoglobulin G (IgG) reactivity to PDIA3 also secreted interferon gamma (IFN-γ) when stimulated in vitro with recombinant PDIA3, whereas those from CRC with low IgG reactivity to PDIA3 did not. PDIA3-pulsed dendritic cells efficiently induced proliferation and IFN-γ production of autologous CD4+ and CD8+ T cells. Finally, ex vivo analysis of tumor-infiltrating T lymphocytes from CRC patients with autoantibodies to PDIA3 revealed that PDIA3-specific Th1 effector cells accumulated in tumor tissue. These data indicate that the presence of autoantibodies to PDIA3 favors the development of an efficient and specific T-cell response against PDIA3 in CRC patients. These results may be relevant for the design of novel immunotherapeutic strategies in CRC patients.

AB - To investigate novel colorectal cancer (CRC)-associated antigens that could be targets of humoral or cellular responses, we analyzed the reactivity of serum from a long-surviving CRC patient (for more than 100 months of follow-up) in clinical remission, by serologic proteome analysis. Two-dimensional Western blotting (2D-WB) and mass spectrometry analysis revealed a strong reactivity of this serum against protein disulfide isomerase A3 (PDIA3). Anti-PDIA3 antibodies are not a diagnostic marker of CRC, 2D-WB and Luminex analysis revealed that they were equally present in about 10% of sera from healthy subjects and CRC patients. Kaplan-Meier analysis of survival in CRC patient cohort, after 48 months of follow-up, showed a trend of higher survival in patients with increased levels of autoantibodies to PDIA3. Therefore, the interplay between the presence of these antibodies and T-cell response was investigated. Peripheral blood T cells from CRC patients with high immunoglobulin G (IgG) reactivity to PDIA3 also secreted interferon gamma (IFN-γ) when stimulated in vitro with recombinant PDIA3, whereas those from CRC with low IgG reactivity to PDIA3 did not. PDIA3-pulsed dendritic cells efficiently induced proliferation and IFN-γ production of autologous CD4+ and CD8+ T cells. Finally, ex vivo analysis of tumor-infiltrating T lymphocytes from CRC patients with autoantibodies to PDIA3 revealed that PDIA3-specific Th1 effector cells accumulated in tumor tissue. These data indicate that the presence of autoantibodies to PDIA3 favors the development of an efficient and specific T-cell response against PDIA3 in CRC patients. These results may be relevant for the design of novel immunotherapeutic strategies in CRC patients.

UR - http://www.scopus.com/inward/record.url?scp=84954290766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954290766&partnerID=8YFLogxK

U2 - 10.1016/j.trsl.2015.12.013

DO - 10.1016/j.trsl.2015.12.013

M3 - Article

VL - 171

SP - 17

EP - 28

JO - Translational Research

JF - Translational Research

SN - 1931-5244

ER -